Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Advaxis, Inc. (ADXS) ADXS-cHER2 Immunotherapy Research Nets Penn One Health Award

|Includes: Advaxis Inc. (ADXS)

Advaxis, a clinical-stage biotechnology company developing the next-generation of immunotherapies for cancer and infectious diseases, today announced that Dr. Nicola Mason, lead investigator of the Penn canine study, and Dr. Yvonne Paterson, scientific founder of Advaxis, have been given the inaugural University of Pennsylvania One Health Award for their research of Advaxis' proprietary immunotherapy, ADXS-cHER2, for the treatment of canine osteosarcoma.

The One Health Award, a new accolade for excellence in promoting One Health initiatives and inter-professional education, was established this year by the deans of the four health schools at Penn - Medicine, Nursing, Veterinary Medicine, and Dental Medicine. The award recognizes exemplary contributions toward expanding interdisciplinary education and improving health care.

"Dr. Paterson and I are delighted to have received the One Health Award for our work using ADXS-cHER2 to prevent metastatic disease in dogs with osteosarcoma. Phase 1 of this clinical trial is almost complete and we have been highly encouraged by the lack of adverse effects of this treatment," stated Dr. Nicola Mason, Chair in Companion Animal Medicine at the University of Pennsylvania School of Veterinary Medicine. "It is too early to comment on the efficacy of the immunotherapy, however, we are encouraged by the data we have obtained so far and are optimistic that immunotherapies such as this one will provide safer and more effective treatment for dogs with cancer in the near future."

ADXS-cHER2, under the direction of Dr. Nicola Mason, is being used to treat dogs suffering from bone cancer. In this trial, dogs that have undergone standard of care treatment for osteosarcoma; including limb amputation and follow up chemotherapy, and that overexpress the tumor marker HER-2/neu in their tumors, are treated with ADXS-cHER2. This immunotherapy is designed to stimulate the dog's immune system to attack cancer cells that express the HER-2/neu marker. The goal is to elicit anti-tumor immunity and prolong survival.

Canine osteosarcoma is a leading killer of large breed dogs that causes tumors to form on long leg bones. The current standard of care is immediate amputation followed by chemotherapy; however, the cancer typically metastasizes, most commonly to the lungs, and causes death in 6-12 months in a percentage of afflicted dogs.

"The award winning research of Dr. Mason and Dr. Paterson establishes that the Advaxis platform technology can be extended to veterinary use," commented Dr. Robert Petit, VP of Clinical Operations and Medical Affairs at Advaxis. "Data from this project will support the further development of our HER-2 targeted immunotherapy against HER-2 overexpressing malignancies in both veterinary and possibly human cancers."

For more information on Advaxis, visit

Please see disclaimer on the QualityStocks website: